Ocugen, Inc.Long
OCUGEN CALLS IDEA!! $7.5 Dec 22
[h1]Best Vaccine pandemic play!![/h1]
Ocugen has just proven to have a vaccine that (Covaxin) can neutralize both Omnicron(most infectious) and the Delta variant(most violent).
Ocugen has seen a beating! Last Quarter the company dropped nearly 50% from previous highs. I'm expecting a return to those highs some time late spring/early summer.
I think $3 is the lowest we can go but, to me its all upside from here! Ocugen could also cause some serious problems for Over- Exposed short sellers.
With T-35 filings piling up and over 25% of the Float in Short interest, this could see a monumental increase in price.
##[h2]The play[/h2]##
Great news behind a great company, professionals have a price target at $10 which is a 110% gain from current levels!!!
My personal Price target is the $20-$25 range.
Recently, I've opened some Dec 22 call options on OCUGEN at $7.5!
Target: 1 | Target: 2 |Target: 3
$11 | $16.50 | $25
Ocugen has just proven to have a vaccine that (Covaxin) can neutralize both Omnicron(most infectious) and the Delta variant(most violent).
Ocugen has seen a beating! Last Quarter the company dropped nearly 50% from previous highs. I'm expecting a return to those highs some time late spring/early summer.
I think $3 is the lowest we can go but, to me its all upside from here! Ocugen could also cause some serious problems for Over- Exposed short sellers.
With T-35 filings piling up and over 25% of the Float in Short interest, this could see a monumental increase in price.
##[h2]The play[/h2]##
Great news behind a great company, professionals have a price target at $10 which is a 110% gain from current levels!!!
My personal Price target is the $20-$25 range.
Recently, I've opened some Dec 22 call options on OCUGEN at $7.5!
Target: 1 | Target: 2 |Target: 3
$11 | $16.50 | $25
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.